Another study from Volpe et al. (2022) evaluated the effectiveness of weekly subcutaneous semaglutide add on to metformin in patients with T2DM eligible for glucagon like peptide 1 receptor agonists (GLP-1 RAs). Here, GLP1R is linked to type 2 diabetes mellitus.